EUVIMEDEUVIMED entdecken
Crossref

EE353 COST-EFFECTIVENESS ANALYSIS OF UBLITUXIMAB FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS

Susmita R. Riya, Khalid M. Kamal

Value in Health · 2026-06 · 29 (6) · S130

DOI: 10.1016/j.jval.2026.03.647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Susmita R. Riya und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Riya, S. R., & Kamal, K. M. (2026). EE353 COST-EFFECTIVENESS ANALYSIS OF UBLITUXIMAB FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS. Value in Health, 29(6), S130. https://doi.org/10.1016/j.jval.2026.03.647

Vancouver

Riya SR, Kamal KM. EE353 COST-EFFECTIVENESS ANALYSIS OF UBLITUXIMAB FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS. Value in Health. 2026;29(6):S130. doi:10.1016/j.jval.2026.03.647

BibTeX
@article{Riya2026,
  author = {Riya, Susmita R. and Kamal, Khalid M.},
  title = {EE353 COST-EFFECTIVENESS ANALYSIS OF UBLITUXIMAB FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {6},
  pages = {S130},
  doi = {10.1016/j.jval.2026.03.647}
}
Kostenlos starten →